Compare IDEXX Laboratories, Inc. (IDXX) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Noble Corporation plc — how do they compare? IDEXX Laboratories, Inc. trades at $516.73 (market cap $40.43B), while Noble Corporation plc trades at $42.5 (market cap $6.73B). The key difference: IDEXX Laboratories, Inc. is far larger — about 6× Noble Corporation plc's market cap, and Noble Corporation plc pays a 4.74% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Noble Corporation plc for 26 Days on average.
| IDXX | NE | |
|---|---|---|
Market Cap | $40.43B | $6.73B |
Volume | 692,164 | 1,027,635 |
Sector | Health | Energy |
52-Week High | $766.68 | $54.37 |
52-Week Low | $504.70 | $26.70 |
Typical Hold Time | 46 Days | 26 Days |
Enterprise Value | $41.32B | $8.16B |
Dividend Yield | — | 4.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Noble Corporation (NE) trades at $42.56, up 3.88% today, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company reported $3.29B revenue for 2025 with a 4.88% net income margin, though recent quarterly earnings have been inconsistent with two misses and one beat. Analyst sentiment is divided with a $52 consensus price target representing 22% upside potential, but ongoing legal investigations create uncertainty.
The stock presents a moderate opportunity with significant analyst upside potential, supported by recent contract wins including the long-term Ghana drilling agreement. However, risks include inconsistent earnings performance, declining profitability margins from 2025 to 2026, and multiple ongoing legal investigations that could impact investor confidence and stock performance in the near term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
